Jon Wigginton MD

Jon Wigginton serves as our President of Research and Development. He has over 25 years of experience in clinical oncology and most recently served as Senior Advisor and Chairman of the Scientific Advisory Board at Cullinan Oncology, Inc., having previously served as the company’s Chief Medical Officer. Prior, Jon was Chief Medical Officer at MacroGenics, where he led the company’s evolution of a fully-integrated clinical-stage cancer immunotherapy organization. Dr. Wigginton also held leadership positions at Bristol Myers Squibb as Therapeutic Area Head and Executive Director, Immuno-Oncology Early Clinical Research and as Group Medical Director of Discovery Medicine-Clinical Oncology. There, he led early clinical development of the BMS Immuno-Oncology portfolio, including checkpoint inhibitors such as anti-PD-1 (Nivolumab)/Opdivo®) and anti-PD-L1 (BMS-936559), checkpoint inhibitor-based combinations including anti-CTLA-4 (Yervoy®)/anti-PD-1 (Opdivo®) among others, and a spectrum of other I-O agents. He also co-founded and co-led the BMS International Immuno-Oncology Network (IION). Dr. Wigginton also previously served as President of the Society for Immunotherapy of Cancer (SITC). Earlier in his career, Dr. Wigginton worked at the National Cancer Institute for 15 years, and served as Head of the Investigational Biologics Section in the Center for Cancer Research (NCI intramural program). There, he demonstrated the initial therapeutic synergy and key mechanisms of action by several novel cytokine-based regimens including IL-2 in combination with IL-18, as well as IL-12 and IL-27 among others. Dr. Wigginton is currently a member of the Board of Directors of Sutro Biopharma. He earned his M.D. and B.S in biology from the University of Michigan.